

=> b reg
FILE 'REGISTRY' ENTERED AT 12:42:24 ON 18 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8
DICTIONARY FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 17
L4 STR



VAR G1=C/N
VAR G2=O/N/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L7 415 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 9030 ITERATIONS 415 ANSWERS
SEARCH TIME: 00.00.01

=> b zcap
FILE 'ZCAPLUS' ENTERED AT 12:42:39 ON 18 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2009 VOL 151 ISS 21
FILE LAST UPDATED: 17 Nov 2009 (20091117/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/Cplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> d bib abs hitrn fhitstr l10 tot

L10 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:570902 ZCPLUS
 DN 143:97403
 TI Pyrido- and pyrimidopyrimidine derivs. as antiproliferative agents
 IN Frans, Eddy Jean Espard; Willems, Marc; Storck, Pierre; Henrict; Poncelat, Virginie Sophie; Van Emelen, Kristof; Bulijntveld, Peter Jacobus Johannes Antonius; Embrechts, Werner Constant Johan; Peeters, Timothy Pietro Suren PA Janssen Pharmaceutica N.V., Belg.
 SG PCT Int. Appl., 64 pp.
 COOPER, PIXXD2
 DT Patent
 LA English
 FAN,CNT 1

PATENT NO. KING DATE APPLICATION NO. DATE
 PI WO-200508913 A1 20050630 2004WO-BP052501 20041215
 M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LY, MD, MG, MK, MN, MR, MT, MU, NE, NG, NL,
 NO, PR, PT, RU, SC, SE, SL, SV, TR, TZ, UA, US, UZ, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AZ, BY, KG, KZ, MD, RU, IJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,
 MR, NE, SN, TD, TZ
 AU-2004298448 A1 20050630 2004AU-000298448 20041215
 CA-2549869 A1 20050630 2004CA-002549869 20041215
 EP-1697384 A1 20060108 2004EP-000804852 20041215
 EP-1697384 B1 20060108 2004EP-000804852 20041215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU
 BR-2004017534 A 20070327 2004BR-000017534 20041215
 JP-20070112 T 20070607 2004JP-000544440 20041215
 AT-391129 T 20080415 2004AT-000804852 20041215
 ES-2305887 T3 20081105 2004ES-000804852 20041215
 US-20070078132 A1 20070405 2006US-000596512 20060615
 ZA-2006004972 A 20081231 2006ZA-0004972 20060615
 IN-200600774 A 20060718 2006IN-00000774 20060616
 MX-2006007017 A 20060821 2006MX-000007017 20060619
 KR-20061267216 A 20061209 2006KR-000714283 20060714
 NO-20060032323 A 20060718 2006NO-000003233 20060718
 PRAI 2003WO-BP052501 A 20031218
 2003WO-BP051062 A 20031218
 2004WO-BP052501 M 20041215
 OS CASREACT 143:97403; MARPAT 143:97403
 GI



AB The present invention concerns pyrido- and pyrimidopyrimidine macrocycle derivatives. One example compound prepared was I. Reactions are given for preparation of a number of intermediates and other derivs. similar to I. Pharmacol. data include in vitro inhibition of EGFR receptors and serum starved proliferation assay on ovarian carcinoma SKOV3 cells.

IT 855995-90-3P 855995-93-6P

L10 ANSWER 1 OF 1 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(pyrido- and pyrimidopyrimidine derivs. prepn. as antiproliferative agents)

IT 855995-91-4P 855995-92-5P 855995-94-7P

855995-95-6P 855995-96-9P 855995-97-0P

855995-98-1P 855995-99-2P 855996-00-8P

855996-01-9P 855996-02-0P 855996-03-1P

855996-04-2P 855996-05-3P 855996-06-4P

855996-07-5P 855996-08-6P 855996-09-7P

855996-10-0P 855996-11-1P 855996-12-2P

PL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrido- and pyrimidopyrimidine derivs. preparation as antiproliferative agents)

IT 855995-90-3P

PL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(pyrido- and pyrimidopyrimidine derivs. preparation as antiproliferative agents)

RN 855995-90-3 ZCPLUS

4,6-Ethlenoprimido(4,5-b)[1,4,6,11]benzotetrazacyclotetradecine,

16-chloro-15-fluoro-1,5,8,11,12,13-hexahydro-12-methyl-, (9E)- (CA INDEX NAME)

Double bond geometry as described by E or Z.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 596512


=> d bib abs hitstr l15 tot

L15 ANSWER 2 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STIN (Continued)
 RN 807642-13-3 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 16-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl- (CA INDEX NAME)



IT 1021691-20-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (macrocyclic quinazoline derivative VEGFR3 VEGF receptor inhibitors, and use with other agents)
 RN 1021691-20-2 ZCPLUS
 CN 4,6-Etheno-12H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 16-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STIN
 AN 2008:529863 ZCPLUS
 DN 148:509908
 TI Use of a macrocyclic quinazoline derivative MT kinase inhibitor for treating or preventing brain cancer
 IN Perera, Timothy Pietro Suren; Page, Martin John; Janicot, Michel Marie Francois; Freyne, Eddy Jean Edgard
 PA Janssen Pharmaceutica NV, Belg.
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2008049901	A1	20080502	2007W0-EP061498	20071025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BS, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GI, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, HU, IE, MR, NE, SN, TD, TG, BW, GH, GM, KE, KZ, LA, LC, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, BY, KG, KE, LK, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, RU, TJ, TM				
US-20080153653	A1	20080626	2007US-000875350	20071019
AU-2007310442	A1	20080502	2007AU-00031042	20071025
CA-20084145	A1	20080502	2007CA-002664145	20071025
EP-2007843	A1	20090715	2007EP-000821861	20071025
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, HU, IE, MR, NE, SN, TD, TG, BW, GH, GM, KE, KZ, LA, LC, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, RU, TJ, TM				

US-20080153653 A1 20080626 2007US-000875350 20071019

AU-2007310442 A1 20080502 2007AU-00031042 20071025

CA-20084145 A1 20080502 2007CA-002664145 20071025

EP-2007843 A1 20090715 2007EP-000821861 20071025

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, HU, IE, MR, NE, SN, TD, TG, BW, GH, GM, KE, KZ, LA, LC, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, RU, TJ, TM

PRAT 2006EDB-000123060 A2 20061027 P 20061027 20070928 20071025

2007US-00076168P P 20070928 20071025

2007W0-EP061498 W 20071025

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention is concerned with the finding that the macrocyclic quinazoline derivative, 4,6-etheno-12H-pyrimido[4,5-b][6,1,10,13]benzoxatriazolo-pentadecine,

17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of a primary brain cancer or brain metastases, and in methods for killing bone cancer cells, for treating or preventing, delaying or mitigating brain cancer, or for preventing or slowing proliferation of cells of brain origin. Compound preparation is described.

IT 807640-87-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(macrocyclic quinazoline derivative MT kinase inhibitor for treatment or prevention of brain cancer)


RN 807640-87-5 ZCPLUS

CN 4,6-Etheno-12H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)

L15 ANSWER 3 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STIN (Continued)



IT 1021686-80-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrocyclic quinazoline derivative MT kinase inhibitor for treatment or prevention of brain cancer)
 RN 1021686-80-5 ZCPLUS
 CN 4,6-Etheno-12H-pyrimido[4,5-b][6,1,12]benzoxatriazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HBr

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STIN
 AN 2008:529205 ZCPLUS
 DN 148:509905

TI Use of MKII 1 for treating or preventing bone cancer
 IN Perera, Timothy Pietro Suren; Janicot, Michel Marie Francois; Meert, Theo Trans; Freyne, Eddy Jean Edgard

PA Janssen Pharmaceutica NV, Belg.

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2008049904	A1	20080502	2007W0-EP061501	20071025
WO-2008049904	A2	20090111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BS, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GI, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, RU, TJ, TM

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, HU, IE, MR, NE, SN, TD, TG, BW, GH, GM, KE, KZ, LA, LC, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, RU, TJ, TM

US-20080213275 A1 20080904 2007US-000875429 20071019

AU-2007310845 A1 20080502 2007AU-003310845 20071025

CA-20084165 A1 20080502 2007CA-002664165 20071025

EP-2007847 A1 20090114 2007EP-000708079 20071025

EP-2101782 A2 20090223 2007EP-000821864 20071025

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, HU, IE, MR, NE, SN, TD, TG, BW, GH, GM, KE, KZ, LA, LC, LS, LU, LY, MA, MD, ME, MG, MN, MO, MR, MT, MU, NA, NI, NO, NG, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, EA, ZM, ZW, AM, AZ, RU, TJ, TM

PRAT 2006EDB-000123060 A2 20061027 P 20061027 20070928 20071025

2007US-00076168P P 20070928 20071025

2007W0-EP061501 W 20071025

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention is concerned with the finding that the macrocyclic quinazoline derivative, 4,6-ethanediyldene-1,5-dihydro-4H-pyrimido[4,5-b][6,1,10,13]benzoxatriazolo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of a medicament for the treatment or prevention of bone cancers and methods for killing bone cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone disease and osteoporosis, and methods for preventing, delaying or mitigating bone cancer, or for preventing and treating of bone loss associated with cancer metastases. Compound preparation is described.


IT 807640-87-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MKII 1 for treating or preventing bone cancer, and use with other agents)


RN 807640-87-5 ZCPLUS

CN 4,6-Etheno-12H-pyrimido[4,5-b][6,1,12]benzoxatriazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN 1001432-00-3 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 23-(3-chloropropoxy)-6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.





IT 1001433-57-3P 1001433-58-4P 1001433-59-5P
 1001433-60-5P 1001433-61-5P
 RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline derivs. as antitumor agents)
 RN 1001433-57-3P 1001433-58-4P 1001433-59-5P
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl- (CA INDEX NAME)




RN 1001433-58-4 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid, 4-bromo-6,9,10,11,12,20-hexahydro-22-[3-(4-methyl-1-piperazinyl)propoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 1001433-59-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[2-(4-piperidinyl)ethoxy- (CA INDEX NAME)




RN 1001433-60-8 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-22-(3-chloropropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001433-61-9 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.


IT 1001431-79-3P 1001431-80-6P 1001431-82-8P
 1001431-83-9P 1001431-84-0P 1001431-85-1P
 1001431-86-2P 1001431-88-4P 1001431-89-5P
 1001431-87-6P 1001431-90-7P 1001431-91-8P
 1001431-95-2P 1001431-97-5P 1001432-02-5P
 1001432-04-7P 1001432-06-9P 1001432-07-0P
 1001432-09-2P 1001432-11-6P 1001432-13-8P
 1001432-15-0P 1001432-17-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazoline derivs. as antitumor agents)
 RN 1001431-79-3 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid, 6,7,8,9,10,11,12,20-hexahydro-22-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001431-80-6 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-methoxy- (CA INDEX NAME)



RN 1001431-82-8 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,2]benzoxadiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl- (CA INDEX NAME)




RN 1001431-83-9 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,2]benzoxadiazacyclopentadecine-22-ol,
 6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001431-84-0 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,2]benzoxadiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[(2S)-2-oxiranylmethoxy]- (CA INDEX NAME)


Absolute stereochemistry.




RN 1001431-85-1 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,
 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7-methyl-1-(2-nitrophenyl)sulfonyl- (CA INDEX NAME)




RN 1001431-86-2 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,
 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7-methyl- (CA INDEX NAME)




RN 1001431-88-4 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-23-ol,
 6,8,9,10,11,12,13,21-octahydro-7-methyl- (CA INDEX NAME)




RN 1001431-89-5 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid,
 6,8,9,10,11,12,13,21-hexahydro-23-hydroxy-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001431-92-0 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid,
 6,8,9,10,11,12,13,21-hexahydro-7-methyl-22-(3-(4-methyl-1-piperazinyl)propoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1001431-93-1 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid,
 6,8,9,10,11,12,13,21-hexahydro-22-(2-methoxyethoxyethoxy)-7-methyl-, (CA INDEX NAME)




RN 1001431-94-2 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid,
 6,8,9,10,11,12,13,21-hexahydro-23-[(2-hydroxyethyl)methylamino]propoxy]-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001431-95-3 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001431-97-5 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-23-hydroxy-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-02-5 ZCPLUS
CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-x]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-morpholinyl)propoxy]-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-04-7 ZCPLUS
CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxyethoxyethoxy)-7,8-dimethyl-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 1001432-11-6 ZCPLUS
CN Ethanol, 2-[methyl-13-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecin-22-yloxy)propyl]amino]- (CA INDEX NAME)




RN 1001432-13-8 ZCPLUS
CN Carbanic acid, N-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecin-22-yloxy)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001432-06-9 ZCPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecine-7(8H)-carboxylic acid, 4-bromo-6,9,10,11,12,20-hexahydro-22-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001432-07-0 ZCPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecine, 22-(3-bromopropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001432-09-2 ZCPLUS
CN 15,17-Etheno-7H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-7-methyl-23-[3-[4-(methylsulfonyl)-1-



RN 1001432-15-0 ZCPLUS
CN 2-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecin-22-yloxy)-3-(methylsulfonyl)-1-



RN 1001432-17-2 ZCPLUS
CN Propanamine, N-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclpentadecin-22-yloxy)propyl]-3-(methylsulfonyl)-




IT 1001431-81-7P 1001431-87-3P 1001431-90-8P
1001431-96-4P 1001431-98-6P 1001432-19-4P
1001432-21-8P 1001432-23-0P 1001432-25-2P
1001432-22-1P 1001432-24-0P 1001432-26-9P
1001432-22-1P 1001432-34-3P 1001432-36-5P
1001432-38-7P 1001432-40-1P 1001432-42-3P
1001432-44-5P 1001432-46-7P 1001432-48-9P
1001432-50-3P 1001432-52-5P 1001432-54-7P
1001432-55-6P 1001432-56-9P 1001432-57-0P
1001432-58-2P 1001432-59-4P 1001432-60-5P
1001432-61-6P 1001432-62-7P 1001432-63-8P
1001432-64-9P 1001432-65-0P 1001432-66-1P

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

1001432-67-2P 1001432-68-3P 1001432-69-4P
 1001432-70-7P 1001432-71-8P 1001432-72-9P
 1001432-73-0P 1001432-74-1P 1001432-75-2P
 1001432-76-3P 1001432-77-4P 1001432-78-5P
 1001432-79-6P 1001432-80-9P 1001432-81-0P
 1001432-82-1P 1001432-83-2P 1001432-84-3P
 1001432-85-4P 1001432-86-5P 1001432-87-6P
 1001432-88-7P 1001432-89-8P 1001432-90-1P
 1001432-91-2P 1001432-92-3P 1001432-93-4P
 1001432-94-5P 1001432-95-6P 1001432-96-7P
 1001432-97-8P 1001432-98-9P 1001432-99-0P
 1001433-00-6P 1001433-01-7P 1001433-02-8P
 1001433-03-9P 1001433-04-0P 1001433-05-1P
 1001433-06-2P 1001433-07-3P 1001433-08-4P
 1001433-09-5P 1001433-10-6P 1001433-11-7P
 1001433-12-8P 1001433-13-9P 1001433-14-2P
 1001433-15-3P 1001433-16-4P 1001433-17-5P
 1001433-18-6P 1001433-19-7P

RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn of quinazoline derivs as antitumor agents)
 CN 1001431-81-7 ZCPLUS
 1,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,10,12]benzoxadiazacyclopentadecine,
 6,7,8,9,10,11,12,21-octahydro-22-methoxy-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HCl


RN 1001431-87-3 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclonexadecine,
 6,7,8,9,10,11,12,21-octahydro-23-methoxy-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 3 HCl

RN 1001431-90-6 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclonexadecine-10(11H)-carboxylic acid,
 23-[(1,1-dimethylethoxy)carbonyl]oxy-6,8,9,12,13,21-hexahydro-7-methyl-1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001431-96-4 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclonexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 1001431-98-6 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclonexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 1001432-19-4 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid,
 6,9,10,11,12,20-hexahydro-23-methoxy-4-[(6-methyl-3-pyridinyl)oxy]-, p-methoxyethyl ester (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1001432-23-8 ZCPLUS
 CN 1-Piperidinethanol, α -[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]methyl-, hydrochloride (1:3), (aS)- (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl


RN 1001432-23-0 ZCPLUS
 CN 1- α -Thiomorpholinethanol, α -[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]methyl-, 1,1-dioxide, hydrochloride (1:3), (aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-25-2 ZCPLUS
 CN 4-Thiomethylheptaneethanol, α -[((6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecin-22-yl)oxy)methyl]-, 1,1-dioxide, hydrochloride (1:3), (aR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-27-4 ZCPLUS
 CN 1,3,5,7,8,10,11,12,20-octahydro-23-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-29-6 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-30-9 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-23-(2-methoxyethoxy)-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.




RN 1001432-32-1 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-[(2-methoxyethoxy)ethoxy]-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)




RN 1001432-34-3 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 22-(3,3-diethoxypropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001432-36-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-(2-methoxyethoxy)-, hydrochloride (1:2)




RN 1001432-38-7 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,13,21-octahydro-7-methyl-23-(3-(4-methyl-1-piperazinyl)propoxy)-, hydrochloride (1:2) (CA INDEX NAME)



RN 1001432-40-1 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,13,21-octahydro-7-methyl-23-(3-(4-morpholinyl)propoxy)-, hydrochloride (1:4) (CA INDEX NAME)




RN 1001432-42-3 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecine,
 6,8,9,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7-methyl-,
 hydrochloride (1:3) (CA INDEX NAME)




MeO-CH₂-CH₂-O-CH₂-CH₂-O-

● 4 HCl

RN 1001432-44-5 ZCPLUS
 CN Ethanol, 2-(methyl[3-((6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-23-yloxy)propyl]amino)-, hydrochloride (1:4) (CA INDEX NAME)



RN 1001432-46-7 ZCPLUS
 CN 1-Propanamine, N-(2-methoxyethyl)-3-((6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-23-yloxy)-, hydrochloride (1:4) (CA INDEX NAME)




MeO-CH₂-CH₂-NH-(CH₂)₃-O-

● 4 HCl

RN 1001432-48-9 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-morpholinyl)propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)



Absolute stereochemistry.



RN 1001432-50-3 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one,
 23-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



RN 1001432-52-5 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one,
 23-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A




RN 1001432-54-7 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-23-[3-(2-methoxyethyl)amino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



● 3 HCl

RN 1001422-55-8 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[3-[(2-hydroxyethyl)amino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 1001422-56-9 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[3-[(2-hydroxyethyl)methylamino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 1001432-57-0 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 1001432-58-6 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-(2-methoxyethoxy)-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 1001422-59-2 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[(2S)-2-oxiranymethoxy]-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-60-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 4-bromo-6,7,8,9,10,11,12,20-octahydro-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 1001432-61-6 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 4-bromo-6,7,8,9,10,11,12,20-octahydro-, (CA INDEX NAME)



RN 1001432-62-7 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 6,7,8,9,10,11,12,20-octahydro-, (CA INDEX NAME)




RN 1001432-63-8 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 6,7,8,9,10,11,12,20-octahydro-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 1001432-64-9 ZCPLUS
 CN 5H-[1,3]Dioxolo[4,5-q]quinazolino(4,5-bc)[5,1,10]benzoxadiazacyclotridecene, 6,7,8,9,10,16-hexahydro-2-methoxy- (CA INDEX NAME)




RN 1001432-65-0 ZCPLUS
 CN [1,3]Dioxolo[4,5-p]quinazolino(4,5-bc)[5,1,11]benzoxadiazacyclotetradecine, 5,6,7,8,9,10,11,17-octahydro-5-methoxy- (CA INDEX NAME)




RN 1001432-66-1 ZCPLUS
 CN 4,6-Etheno[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 1001432-67-2 ZCPLUS
 CN 4,6-Etheno[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine-12(13H)-carboxylic acid, 6,9,10,11,14,20-hexahydro-21-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001432-67-2 ZCPLUS
 CN 4,6-Etheno[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine-12(13H)-carboxylic acid, 6,9,10,11,14,20-hexahydro-21-methoxy-, phenylmethyl ester (CA INDEX NAME)



RN 1001432-68-3 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-22-ol, 4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001432-69-4 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 1001432-70-7 ZCPLUS
 CN 4,6-Etheno[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-21-methoxy-12-methyl- (CA INDEX NAME)




RN 1001432-71-8 ZCPLUS
 CN 4,6-Etheno[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-21-methoxy-12-methyl-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 1001432-72-9 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecine, 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7,10-dimethyl- (CA INDEX NAME)




RN 1001432-73-0 ZCPLUS
 CN 15,17-Etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecine, 7,8,9,10,11,12,13,21-octahydro-23-methoxy-7,10-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)




●3 HCl

RN 1001432-74-1 ZCPLUS
 CN 15,17-Etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecine-23-ol, 7,8,9,10,11,12,13,21-octahydro-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl


RN 1001432-75-2 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,13,21-octahydro-7-methyl-22-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)




RN 1001432-76-3 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,1,2]benzodiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(4-morpholinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)




RN 1001432-77-4 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,1,2]benzodiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-piperidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)



RN 1001432-78-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,1,2]benzodiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-pyrrolidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)





RN 1001432-79-6 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,1,2]benzodiazacyclopentadecine,
 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)





RN 1001432-80-9 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][1,2,10,13]benzodiazatriazacyclohexadecin-9-one,
 6,7,8,9,10,11,12,13,21-octahydro-23-[3-(4-(2-hydroxyethyl)-1-piperazinyl)propoxy]-, 9-dimethyl-, hydrochloride (1:4), (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1001432-81-0 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][1,2,10,13]benzodiazatriazacyclohexadecin-9-one,
 8,9,10,11,12,13,14,21-octahydro-23-[3-(4-(2-(methylsulfonyl)ethyl)-1-piperidinyl)propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-82-1 ZCPLUS
 CN 15,17-Etheno-9H-(1,3)dioxolo[4,5-r]pyrimido[4,5-b][1,2,10,13]benzodiazatriazacyclohexadecin-9-one,


L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-(methylsulfonyl)-1-piperidinyl)propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1001432-84-3 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (1:3) (CA INDEX NAME)

PAGE 2-A




●3 HCl

RN 1001432-83-2 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (1:3) (CA INDEX NAME)



RN 1001432-85-4 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-(3-(1-pyrrolidinyl)propoxy)-, hydrochloride (1:3) (CA INDEX NAME)


L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



●3 HCl

RN 1001432-86-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-[(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)

PAGE 1-A





●4 HCl

RN 1001432-87-6 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecin-9-ene, 6,7,8,9,10,11,12,13,21-octahydro-8,8-dimethyl-23-[(4-methyl-1-piperazinyl)propoxy]-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




PAGE 1-A

RN 1001432-88-7 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecin-9-ene, 6,7,8,10,11,12,13,21-octahydro-8,8-dimethyl-23-[(4-methyl-1-




RN 1001432-88-7 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecin-9-ene, 6,7,8,10,11,12,13,21-octahydro-8,8-dimethyl-23-[(4-methyl-1-

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 (8S)- (CA INDEX NAME)
 Absolute stereochemistry.




PAGE 1-A



L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 PAGE 1-A



PAGE 2-A



PAGE 2-A

● 4 HCl

RN 1001432-98-6 ZCPLUS
 CN 15,17-etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one,
 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-(3-(methylsulfonyl)-1-oxopropyl)-1-piperazinyl)propoxy]-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1001432-90-1 ZCPLUS
 CN Acetamide, N-[2-(4-[(7,8,9,10,11,12,13,21-octahydro-7,8-dimethyl-9-oxo-15,17-etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-23-yl)oxy]propyl)-1-piperazinyl]ethyl]-, hydrochloride (1:4) (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


PAGE 1-A



PAGE 1-A



PAGE 2-A




PAGE 2-A

● 4 HCl

RN 1001432-93-2 ZCPLUS
 CN Acetamide, N-[2-(4-[(7,8,9,10,11,12,13,21-octahydro-7,8-dimethyl-9-oxo-15,17-etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,12]benzoxadiazacyclonadecin-23-yl)oxy]propyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 1001432-92-3 ZCPLUS
 CN 1-Piperazineethanol, 1-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclonadecin-22-yl)oxy]propyl]- (CA INDEX NAME)





RN 1001432-93-4 ZCPLUS


CN 1-Propanone, 1-[4-(2-((6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxyethyl)-1-piperidinyl-3-(methylsulfonyl)-, hydrochloride (1:2) (CA INDEX NAME)


PAGE 1-A



L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 PAGE 1-A



PAGE 2-A




PAGE 2-A

RN 1001432-94-5 ZCPLUS
 1-Piperazineethanol, 4-[(3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)- (CA INDEX NAME)


RN 1001432-95-6 ZCPLUS
 15,17-Ethano-2H-[1,3]dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-6,8,9,10,11,12,13,21-octahydro-7-methyl-23-[(3-[(4-(methylsulfonyl)-1-piperidinyl)propoxy]-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A




L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 1001432-98-9 ZCPLUS
 Ethanolo, 2-[(3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)amino]-, hydrochloride (1:3) (CA INDEX NAME)




PAGE 2-A



●3 HCl


RN 1001432-99-0 ZCPLUS
 1-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]-N-(2-methoxyethyl)-, hydrochloride (1:3) (CA INDEX NAME)

RN 1001432-96-7 ZCPLUS
 Ethanolo, 2-[(3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)methylamino]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl


RN 1001432-97-8 ZCPLUS
 1-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]-N-(2-(methylsulfonyl)ethyl)-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 1001433-00-6 ZCPLUS
 Ethanolo, 2-[(3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]-N-(2-methoxyethyl)-, hydrochloride (1:3)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN 16,1,12]benzoxadiazacyclopentadecin-22-yl)oxy|propyl|amino)- (CA INDEX NAME)




RN 1001433-01-7 ZCPLUS
 CN Ethanol, 2-[[3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecin-22-yl)oxy|propyl|methylamino)- (CA INDEX NAME)




RN 1001433-02-8 ZCPLUS
 CN Propanamide, N-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecin-22-yl)oxy|propyl]-3-(methylsulfonyl)-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




● 2 HCl

RN 1001433-03-9 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-methoxy-4-((6-methyl-3-pyridinyl)oxy)-, hydrochloride (1:3) (CA INDEX NAME)




RN 1001433-04-0 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][16,1,12]benzoxadiazacyclopentadecine-4-carbonitrile, 6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl-, (8S)- (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 1001433-05-1 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]benzoxatriazacyclonexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1001433-06-2 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 1001433-07-3 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001433-08-4 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001433-09-5 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][16,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001423-10-8 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,8-trimethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl
 RN 1001423-11-9 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,8-trimethyl- (CA INDEX NAME)




RN 1001423-12-0 ZCPLUS
 CN 1-Piperidinet ethanol, α -{[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-


Absolute stereochemistry.




RN 1001423-13-1 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,7,8,9,10,11,12,20-octahydro-23-(2-methoxyethoxy)-7-methyl- (CA INDEX NAME)




RN 1001423-14-2 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-(3-(4-methyl-1-piperazinyl)propoxy)- (CA INDEX NAME)




RN 1001423-15-3 ZCPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7-methyl- (CA INDEX NAME)




RN 1001423-16-4 ZCPLUS
 CN Ethanol, 2-[methyl13-[(6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-23-yl)oxy]propyl]amino)- (CA INDEX NAME)



RN 1001423-17-5 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy- (CA INDEX NAME)




RN 1001423-18-6 ZCPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 1001423-19-7 ZCPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-(3-(4-(methylsulfonyl)-1-piperidinyl)propoxy)- (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



L15 ANSWER 7 OF 7 ZCPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:1330060 ZCPLUS
 DN 146:229297
 TI Synthesis of new flat polyheterocyclic systems, potential DNA
 intercalating agents. Dizaines Part 47
 AU Paudoux, Jerome; Achelle, Sylvain; Turck, Alain; Marsais, Francis; Ple,
 Nelly
 CS Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.), Universite de
 Paris-Sud, 91405 Saint-Aignan, F-76131, Fr.
 SO Journal of Heterocyclic Chemistry (2006), 43(6), 1497-1503
 CODEN: JHTCDB ISSN: 0022-132X
 PB HeteroCorporation
 DT Journal
 LA English
 OS 146:229297
 AB Using a regioselective metalation in connection with Stille cross-coupling
 reaction, various flat tetra- or pentaheterocyclic compds. were obtained
 which could be potential intercalating DNA agents.
 IT 924309-43-3P
 RL: prep synthetic preparation; PREP (Preparation)
 (preparation of new flat polyheterocyclic systems as potential DNA
 intercalating agents)
 RN 924309-43-3 ZCPLUS
 CN 7H-Benzo[c]pyrimido[4,5,6-ij][2,6]naphthyridine, 5-(1,1-dimethylethyl)-
 (CA INDEX NAME)



PAGE 2-A


OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 596512

=> d bib abs hitstr l14 tot

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:578288 ZCPLUS
 DN 145:62924
 TI Preparation of quinazoline derivatives as multi targeting kinase inhibitors
 IN Freyne, Eddy Jean Edgard; Willems, Marc; Ten Holte, Peter; Papanikos, Alexandra; Embrechts, Werner Constant Johan; Storck, Pierre Henri; Poncelet, Virginie Sophie
 PA Janssen Pharmaceutica N.V., Belg.
 SO Acta Pol. Appl., 88 pp.
 CODEN: PIXX2D
 DT Patent
 LA English
 FAN.CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO-2006014117 A2 20060615 2005WO-EP056609 20051208 <--
 WO-2006014117 A3 20060803 20051208 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CR, CS, DE, DK, ES, FI, GB, GR, HK, HR, IL, IN, IS, JP, KE, KG, KM, KR, KP, KR,
 KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 RW: VN, ZW
 IS: IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ,
 CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 AU-2005123208 A1 20050615 2005AU-000213250 20051208 <--
 CA-2005123208 A3 20060615 2005CA-002588764 20051208 <--
 EP-2005123208 A2 20070905 2005EP-000826362 20051208 <--
 R: AI, BE, BG, CH, CI, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN-2005127034 A 20050713 2005CN-000494213 20051208 <--
 JP-2008523034 T 20080703 2007JP-000544918 20051208 <--
 BR-200518394 A2 20080118 2005BR-000018394 20051208 <--
 IN-200704039 A 20070821 2007IN-000004039 20070529 <--
 MX-200706620 A 20070724 2007MX-000064620 20070607 <--
 ZA-200706646 A 20070724 2007ZA-00006464 20070607 <--
 KR-200708630 A 20070827 2007KR-000712123 20070611 <--
 NO-200703426 A 20070705 2007NO-000003426 20070705 <--
 PPAI 2004EP-00106383 A 20041208 <--
 2004US-00634228P P 20041208 <--
 2004EP-00106385 A 20041208 <--
 2005WO-EP056609 M 20051208 <--
 OS CASREACT 145:62924; MARPAT 145:62924
 GI




AB Title compds. represented by the formula I (wherein Z = NH; X = alkenyl, alkanyl, alkyl-NHCO, etc.; X1 = O, -O-(alkyl), -O-NmCH-, (un)substituted amino(alkyl); X2 = a direct bond, alkyl, amino, etc.; R1 = H, cyano, halo or hydroxy; R2 = H, cyano, halo, etc.; R3 = H, cyano,

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 formyl, etc.; R4 = (un)substituted (phenyl)alkyloxy; and N-oxides, pharmaceutically acceptable addn. salts and the stereochem. isomeric forms thereof were prep. as multi targeting kinase inhibitors (MTK). For example, I was derived in a multi-step synthesis starting from N-(4-(4-chloro-2-nitrophenyl)acetyl)glycine Et ester. I were tested for inhibition of Abl human, CDK5/p35 human, cSRC human and the other kinases. Thus, I and their pharmaceutical compns. are useful as MTK for the treatment of cell proliferative disorders, such as atherosclerosis prevention and cancer prevention.


IT 807641-08-3P 890532-88-4P 890532-90-8P
 890532-92-0P 890532-94-2P 890532-96-4P
 890532-98-6P 890532-99-3P 890533-01-4P
 890533-02-5P 890533-03-6P 890533-04-7P
 890533-05-7P 890533-06-9P 890533-07-0P
 890533-08-1P 890533-09-2P 890533-10-4P
 890533-11-6P 890533-12-7P 890533-13-8P
 890533-14-9P 890533-15-0P

PJ: PAC (Pharmacological activity); SP: (Synthetic preparation); THU (Therapeutic activity); BTOL (Biological study); PREP (Preparation); USES (Uses);
 (preparation of quinazoline derivs. as multi targeting kinase inhibitors);
 RN 807641-08-3 ZCPLUS
 CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-1,2-methoxy-10-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 890532-88-4 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-
 one, 21-[3-[2-(acetyl)oxy]ethyl]methylaminolpropoxy-18-chloro-17-fluoro-
 8,9,10,11,13,14,15,20-octahydro-13-[2-(2-hydroxyethyl)methylamino]propoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-90-8 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-
 one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-[3-(2-hydroxyethyl)methylamino]propoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 890532-92-0 ZCPLUS
 CN Acetamide, N-[2-((13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-yl)oxy]propyl|amino|ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 890532-94-2 ZCPLUS
 CN Acetamide, N-[3-((13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-yl)oxy]propyl|-N-(2-hydroxyethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-96-4 ZCPLUS
 CN Acetamide, N-[2-((13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-yl)oxy]propyl|-1-piperazinyl|ethyl- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 890532-98-6 ZCPLUS
 CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-ethyl-11,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)-11-[3-(4-morpholinyl)propyl]-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890533-00-3 ZCPLUS
 CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-13-(cyclohexylmethyl)-8,9,10,11,13,14,17,22-octahydro-23-methoxy-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890533-01-4 ZCPLUS


L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine,
 17-ethynyl-1,8,9,10,11,12,13,14-octahydro-20-[2-(2-methoxyethoxy)ethoxy]-
 13-methyl- (CA INDEX NAME)



RN 890533-02-5 ZCPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine,
 18-bromo-17-fluoro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-
 11-[(2-nitrophenyl)sulfonyl]-(CA INDEX NAME)




RN 890533-03-6 ZCPLUS
 CN Carbamic acid, 15-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-yl)oxy]propyl-,
 1,1-dimethylsilyl ester (9CI) (CA INDEX NAME)




RN 890533-04-7 ZCPLUS
 CN 2-Thiomethyl-1,1-dimethyl-1,1-dioxo-2-[(17-bromo-1,8,9,10,11,12,13,14-
 octahydro-13-methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-yl)oxy]methyl-, 1,1-dioxide,
 (methylsulfonyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-05-8 ZCPLUS
 CN Acetamide, N-[2-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-
 4,6-ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-
 yl)oxy]propyl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 890533-06-9 ZCPLUS
 CN 1-Propanamine, 3-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-yl)oxy]-N-[2-(
 methoxysulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 890533-07-0 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine-12,15-
 dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy-11-[2-(4-
 morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-08-1 ZCPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine,
 18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-
 11-[(2-nitrophenyl)sulfonyl]-(CA INDEX NAME)




RN 890533-09-2 ZCPLUS
 CN 2-Propanol, 1-[(17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-13-
 methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-
 yl)oxy]-3-[(2-(2-hydroxyethoxy)ethyl)amino]-(2R)- (9CI) (CA INDEX NAME)




RN 890533-10-5 ZCPLUS
 CN 1-Propanamine, 3-[(17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-13-
 methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-
 yl)oxy]-N-[(2-methoxysulfonyl)ethyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-11-6 ZCPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine,
 17-chloro-20-[(3-(1,1-dioxido-4-chlormorpholinyl)propoxy)-16-fluoro-
 1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)




RN 890533-12-7 ZCPLUS
 CN D-Propanamine, 3-[(17-ethynyl-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadec-20-yl)oxy]-N-[2-(
 methoxysulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 890533-13-8 ZCPLUS
 CN Spiro[16H-6H-pyrimido[4,5-b][6,1,10,13]benzodiazacyclopentadecine-13(14H),1'-cyclohexane]-12,15-
 dione, 20-chloro-8,9,10,11,17,22-hexahydro-23-methoxy- (CA INDEX NAME)


L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-34-9 ZCPLUS
8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-ol, 18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-14-methyl-11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)



RN 890533-15-0 ZCPLUS
8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-ol, 18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-14-methyl-11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




IT 890532-56-0P 890532-65-7P 890532-76-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THD (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as multi targeting kinase inhibitors for

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
treatment of cell proliferation disorders)


RN 890532-56-6 ZCPLUS
CN 1-Piperazine-4-carboxylic acid, 3-[(13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-14-methyl-12-oxo-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-yl]oxy]propyl]-, 1,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-65-7 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-bromo-1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)-11-[(4-morpholinyl)propyl]-, (13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 890532-76-0 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzodiazazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-[2-(2-methoxyethoxy)ethoxy]-13-methyl- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




IT 807640-87-5P 890532-53-3P 890532-54-4P
890532-55-5P 890532-57-7P 890532-66-8P
890532-75-9P 890532-77-1P 890532-84-0P
890532-86-1P 890532-87-5P

RL: PAC (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as multi targeting kinase inhibitors for


treatment of cell proliferation disorders)

RN 807640-87-5 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzodiazazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)



RN 890532-53-3 ZCPLUS
12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 890532-54-4 ZCPLUS
12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-hydroxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 1 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 890532-55-5 ZCPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-21-(3-chloropropoxy)-17-fluoro-8,9,10,11,13,14,15,20-octahydro-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-57-7 ZCPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-13,14-dimethyl-21-(1-piperazinyl)propoxy-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-66-8 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)-11-[(3-morpholinyl)propyl]-19-(trimethylsilyl)ethynyl-, (13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 890532-75-9 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine-20-ol, 17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)



RN 890532-77-1 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 1,8,9,10,11,12,13,14-octahydro-20-[2-(2-methoxyethoxy)ethoxy]-13-methyl-17-[2-(trimethylsilyl)ethyl] (9CI) (CA INDEX NAME)



RN 890532-84-0 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-20-((25)-oxiranymethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

AN 2004:1059178 ZCPLUS
DN 142:38270
TI A preparation of macrocyclic quinazoline derivatives, useful as antiproliferative agents
IN Preys, Eddy Jean Edgard; Perera, Timothy Pietro Suren; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marci; Diels, Gaston Stanislas Marcella; Embrechts, Werner Constant Johan; Ten Holte, Peter Janssen Pharmaceutica N.V.. Beig.

SO PCT Int. Appl. 1, 196 pp.
COPR. PIXXD2
DT Patent
LA English


FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO-2004105765 A1 20041209 2004WO-EP0005621 20040525 <-
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC, LV, LS, LT, MT, MU, MZ, NA, NL, NO, OM, PG, PH, PL, PT, RO, PU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TI, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, ZG
AU-2004243487 A1 20041209 2004AU-000243487 20040525 <-
CA-2004-2525214 A1 20041209 2004CA-002525214 20040525 <-
EP-2004-13365 A1 20041209 2004EP-0013365 20040525 <-
R: A1, B1, B2, CH, DE, DK, ES, FR, GB, IE, IL, LU, NL, SE, MG, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, IR, BG, CZ, EE, HU, PL, SK, HR, BR-2004010714 A 20060613 2004BR-00010714 20040525 <-
CN-2004-1794996 A 20060628 2004CN-080014512 20040525 <-
JP-20075042276 T 20070308 2004JP-0005042276 20040525 <-
IN-20050554 A 20080111 2004IN-000554154 20040525 <-
IN-2005055320 A 20080104 2005IN-000005320 20051121 <-
US-20060247237 A1 20061102 2005US-000558007 20051122 <-
ZA-2005059541 A 20070228 2005ZA-000009541 20051124 <-
MX-2005054052 A 20080128 2005MX-00001762 20051125 <-
NO-2004-0063196 A 20080128 2005NO-000006196 20051227 <-
PCT 2003WO-EP0005723 A 20030527 <-
2003WO-EP010266 A 20030915 <-
2003WO-EP051061 A 20031218 <-
2004WO-EP0005621 W 20040525 <-
OS MARPAT 142:38270
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a preparation of macrocyclic derivs. of formula I (wherein: Z is O, CH₂, NH, or S; Y is alk(en)ynyl, alky, C(=O)NH, C(=O)alkyl, or C(=O)alkenyl, etc.; R₁ is H, CN, halogen, OH, CHO, or alkyl, etc.; R₂ is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R₃ is H, OH, or alkyl; R₄ is H, OH, aryloxy, alkoxyl, or alkenyloxy, etc.), useful as antiproliferative agents. For instance, pyrimido[4,6-*b*]benzodiazacyclopentadecine derivative II (kinase activity: picG5 = 7.8, A540 = 1.1, picG5 = 1.1, A540 = 1.1, IC₅₀ = 1.1, IC₅₀ = 1.1, heterocyclization/etherification of the prepared quinazoline derivative III. 807639-89-0P 807640-75-1P 807640-80-8P 807640-81-9P 807640-84-2P 807640-94-4P 807640-95-5P

II: RU: (pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)


RN 890532-80-0 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)




RN 890532-85-1 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine, 17-bromo-20-[3-(bromopropoxy)-1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)




OGC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT




RN 807640-75-6 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine-17-carboxylic acid, 8,9,10,11,12,13-hexahydro-20-methoxy-, methyl ester (CA INDEX NAME)



RN 807640-80-8 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-(phenylmethoxy)- (CA INDEX NAME)




RN 807640-81-9 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine-20-ol, 17-bromo-8,9,10,11,12,13-hexahydro- (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 807640-84-2 ZCPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazazacyclopentadecine-13(8H)-carboxylic acid, 17-bromo-9,10,11,12,14,19-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 807640-94-4 ZCPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazazacyclopentadecine-13(8H)-carboxylic acid, 17-chloro-16-fluoro-9,10,11,12,14,19-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 807640-96-6 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,11]benzodiazazacyclopentadecine-12(1H)-carboxylic acid, 17-chloro-9,10,11,13,14-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 807640-67-1P 807640-68-2P 807640-69-3P
 807640-70-6P 807640-71-7P 807640-72-8P
 807640-73-9P 807640-74-0P 807640-76-2P
 807640-77-3P 807640-78-4P 807640-79-5P
 807640-82-0P 807640-83-1P 807640-85-3P
 807640-86-4P 807640-87-5P 807640-88-6P
 807640-89-7P 807640-90-0P 807640-91-1P
 807640-93-3P 807640-95-5P 807640-97-7P

L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 807640-69-3 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807640-70-6 ZCPLUS
 CN 19H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,12,1]benzodioxazaazacyclotetradecine, 16-chloro-9,10,11,12-tetrahydro-19-methoxy- (CA INDEX NAME)




RN 807640-71-7 ZCPLUS
 CN 19H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,12,1]benzodioxazaazacyclotetradecine, 9,10,11,12-tetrahydro-19-methoxy- (CA INDEX NAME)



L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 807640-98-8P 807640-99-9P 807641-00-5P
 807641-01-6P 807641-02-7P 807641-03-8P
 807641-04-9P 807641-05-1P 807641-06-2P
 807641-07-3P 807641-08-4P 807641-09-5P
 807641-10-7P 807641-11-8P 807641-12-9P
 807641-13-0P 807641-14-1P 807641-15-2P
 807641-16-3P 807641-17-4P 807641-18-5P
 807641-19-6P 807641-20-7P 807641-21-8P
 807641-22-9P 807641-23-0P 807641-24-1P
 807641-25-4P 807641-26-5P 807641-27-6P
 807641-28-7P 807641-29-8P 807641-30-1P
 807641-31-2P 807641-32-3P 807641-33-4P
 807641-34-5P 807641-35-6P 807641-36-7P
 807641-37-8P 807641-38-9P 807641-39-0P
 807641-40-3P 807641-41-4P 807641-42-5P
 807641-43-6P 807641-44-7P 807641-45-8P
 807641-46-9P 807641-47-0P 807641-48-1P
 807641-49-2P 807641-50-3P 807641-51-4P
 807641-52-5P 807641-53-6P 807641-54-7P
 807641-55-8P 807641-56-1P 807641-57-2P
 807641-58-3P 807641-59-4P 807641-60-5P
 807641-61-6P 807641-62-7P 807641-63-8P
 807641-64-1P 807641-65-2P 807641-66-3P
 807641-67-4P 807641-68-5P 807641-69-6P
 807641-70-9P 807641-71-0P 807641-72-1P
 807641-73-2P 807641-74-3P 807641-75-4P
 807641-76-5P 807641-77-6P 807641-78-7P
 807641-79-8P 807641-80-1P 807641-81-2P
 807641-82-3P 807641-83-4P 807641-84-5P
 807641-85-6P 807641-86-7P 807641-87-8P
 807641-88-9P 807641-89-0P 807641-90-1P
 807641-91-4P 807641-92-5P 807641-93-6P
 807641-94-7P 807641-95-8P 807641-97-0P
 807641-98-1P 807641-99-2P 807642-00-3P
 807642-01-4P 807642-02-5P 807642-03-6P
 807642-04-7P 807642-05-8P 807642-06-9P
 807642-07-5P 807642-08-6P 807642-09-7P
 807642-10-8P 807642-11-1P 807642-12-2P
 807642-13-3P 807642-14-4P 807642-15-5P
 807642-16-6P 807642-17-7P 807642-18-8P
 807642-20-2P 807642-21-3P 807642-22-4P
 807642-23-5P 807642-24-6P 807642-25-7P
 807642-26-8P 807642-27-9P 807642-28-0P

RN 807642-01-1 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecine-8(9H)-one, 10,11,12,13-tetrahydro-20-methoxy-15-methyl- (CA INDEX NAME)


RN 807640-68-2 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecine.

L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 807640-72-8 ZCPLUS
 CN 20H-4,6-Etheno-6H-pyrimido[4,5-b][6,14,1]benzodioxazaazacyclohexadecine, 18-chloro-9,10,11,12,13,14-hexahydro-21-methoxy- (CA INDEX NAME)



RN 807640-73-9 ZCPLUS
 CN 21H-4,6-Etheno-6H-pyrimido[4,5-b][6,15,1]benzodioxazaazacycloheptadecine, 19-chloro-8,9,10,11,12,13,14,15-octahydro-22-methoxy- (CA INDEX NAME)




RN 807640-74-0 ZCPLUS
 CN 22H-4,6-Etheno-6H-pyrimido[4,5-b][6,16,1]benzodioxazaazacyclooctadecine, 20-chloro-9,10,11,12,13,14,15,16-octahydro-23-methoxy- (CA INDEX NAME)




RN 807640-76-2 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecine-17-


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
carboxylic acid, 8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807640-77-3 ZCPLUS
CN Methanone, 8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxaazacyclopentadecin-17-yl)-1-pyrrolidinyl- (CA INDEX NAME)




RN 807640-78-4 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxaazacyclopentadecine-17-carbonitrile, 8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807640-79-5 ZCPLUS
CN Methanone, (8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxaazacyclopentadecin-17-yl)-4-morpholinyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807640-82-0 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxaazacyclopentadecine, 16-bromo-8,9,10,11,12-tetrahydro-19-(3-(4-morpholinyl)propoxy)- (CA INDEX NAME)




RN 807640-83-1 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxaazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro- (CA INDEX NAME)




RN 807640-85-3 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807640-86-4 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1]benzoxaazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)



RN 807640-87-5 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN 807640-88-6 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,1]benzodioxaazacyclopentadecine, 17-chloro-8,9,10,11,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807640-89-7 ZCPLUS


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
23H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,16]benzoxadiazacyclonadecine, 21-chloro-8,9,10,11,12,13,14,15-octahydro-24-methoxy- (CA INDEX NAME)




RN 807640-90-0 ZCPLUS
CN 19H-4,6-Etheno-17,21-methenopyrimido[5,4-d][1,12,6]dioxaaazacycloeicosine, 8,9,10,11,12,13,14,15-octahydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807640-91-1 ZCPLUS
CN 4,6-Etheno-6H-pyrimido[4,5-b][6,1,10]benzoxadiazacyclopentadecin-12(1H)-one, 17-chloro-8,9,10,11,13,14-hexahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-93-3 ZCPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,13]benzodioxaazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-(2-methoxyethoxy)- (CA INDEX NAME)




RN 807640-95-5 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine,
 17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-97-7 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine,
 17-chloro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-98-8 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[5,4-k][1,8,9,13]benzodioxadiazacyclopentadecine,
 17-chloro-8,9,10,11,12,13-hexahydro-20-methoxy-10-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 807640-99-9 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,13]benzoxadiazacyclopentadecine,
 8,9,10,11,12,13-hexahydro-20-methoxy-17-phenyl- (CA INDEX NAME)




RN 807641-00-5 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,13]benzoxadiazacyclopentadecine-15(8H)-one,
 18-chloro-9,10,11,12,13-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-01-6 ZCPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,13]benzoxadiazacyclopentadecine,
 16-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807641-02-7 ZCPLUS
 CN 14H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,1]benzodioxazacyclopentadecine,
 18-chloro-9,10,11,12,15,20-hexahydro-21-methoxy- (CA INDEX NAME)




RN 807641-03-8 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine-11(8H)-one,
 18-chloro-9,10,12,13,14,15-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-04-9 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(13H)-one,
 19-chloro-8,9,10,11,14,15,16,21-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-05-0 ZCPLUS




RN 807641-06-1 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(13H)-one,
 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-methyl- (9CI) (CA INDEX NAME)




RN 807641-07-2 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine,
 17-bromo-16-fluoro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807641-08-3 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione,
 16-chloro-9,10,12,13-tetrahydro-21-methoxy-10-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 807641-09-6 ZCPLUS
Benzamide, 4-fluoro-N-(8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-16-yl)- (CA INDEX NAME)



RN 807641-10-7 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12,12-dimethyl- (9CI) (CA INDEX NAME)




RN 807641-11-8 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,10,14]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-12-9 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[2,1-16,1,11-14]benzoxatriazacycloheptadecin-13(8H)-one, 21-chloro-18-fluoro-1,8,9,10,11,12,13a,14,15,16,18-decahydro-24-methoxy-, (13aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-13-0 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[2,1-16,1,10,13]benzoxatriazacyclohexadecin-12(1H)-one, 20-chloro-19-fluoro-1,8,9,10,11,12a,13,14,15,17-decahydro-23-methoxy-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-14-1 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,16]benzoxadiazacyclononadecin-16(1H)-one, 21-chloro-8,9,10,13,14,15,17,18-octahydro-24-methoxy-, (11E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 807641-15-2 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,16]benzoxadiazacyclononadecin-16(1H)-one, 21-chloro-8,9,10,13,14,15,17,18-octahydro-24-methoxy-, (11E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 807641-16-3 ZCPLUS
CN Carboxamic acid, [(11E,14S)-20-chloro-8,9,10,13,14,15,16,17-octahydro-23-methoxy-15-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-14-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 807641-17-4 ZCPLUS
CN Carboxamic acid, [(11E,14S)-20-chloro-8,9,10,13,14,15,16,17-octahydro-23-methoxy-15-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-14-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.




RN 807641-18-5 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-15(8H)-one, 14-amino-20-chloro-8,9,10,13,14,16,17-hexahydro-23-methoxy-, dihydrochloride, (14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




● 2 HCl

RN 807641-19-6 ZCPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,
 18-chloro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA
 INDEX NAME)




RN 807641-20-9 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzodiazacyclopentadecine,
 17-chloro-1,8,9,12,13,14-hexahydro-20-methoxy-13-methyl-, (10Z)- (9CI)
 (CA INDEX NAME)


Double bond geometry as shown.



RN 807641-25-4 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-
 9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-methyl-
 (CA INDEX NAME)




RN 807641-26-5 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-
 9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-(1-
 methylethyl)- (CA INDEX NAME)




RN 807641-27-6 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-
 9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-(
 phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 807641-22-1 ZCPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,9,14]benzoxatriazacycloheptadecine-
 9,12(8H,15H)-dione, 19-chloro-10,11,12,13,16,21-hexahydro-22-methoxy- (CA
 INDEX NAME)




RN 807641-23-2 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b]pyrrolid[2,1-
 k][6,1,9,12]benzoxatriazacyclopentadecine-11(8H)-one,
 19-chloro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX
 NAME)




RN 807641-24-3 ZCPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-
 11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy- (CA
 INDEX NAME)




RN 807641-28-7 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-
 dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy- (9CI) (CA
 INDEX NAME)




RN 807641-29-8 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-
 9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-methyl- (CA
 INDEX NAME)




RN 807641-30-1 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-
 9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-(1-methylethyl)-
 (CA INDEX NAME)





RN 807641-31-2 ZCPLUS
CN 19H-9,11-Ethenopyrimido[4,5-b]pyrrololo[1,2-1]1,6,1,9,12]benzoxatriazacyclopentadecine-14,19(5H,13H)-dione, 16,17,18,18a,20,21-hexahydro-22-methoxy- (CA INDEX NAME)




RN 807641-32-3 ZCPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy- (CA INDEX NAME)




RN 807641-33-4 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclonexadecine-9,13(8H,10H)-dione, 11,12,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-35-6 ZCPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-18-methyl- (CA INDEX NAME)




RN 807641-36-7 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-37-8 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,14]benzoxatriazacyclooctadecine-9,14(8H,15H)-dione, 20-chloro-10,11,12,13,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-38-9 ZCPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,12,16]benzoxatriazacyclononadecine-12,16-dione, 21-chloro-8,9,10,11,13,14,15,17,18,23-decahydro-24-methoxy- (CA INDEX NAME)




RN 807641-39-0 ZCPLUS
CN 18H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,17]benzoxatriazacycloicosine-12,17-dione, 22-chloro-8,9,10,11,13,14,15,16,19,24-decahydro-25-methoxy- (CA INDEX NAME)




RN 807641-40-3 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,15(8H,12H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-10-methyl- (9CI) (CA INDEX NAME)




RN 807641-41-4 ZCPLUS
CN Carnosic acid, 18-chloro-8,9,10,11,12,13,14,15-octahydro-21-methoxy-13-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,13]benzoxadiazacyclohexadecin-12-yl)-1,1-dimethylsilyl ester (9CI) (CA INDEX NAME)



RN 807641-42-5 ZCPLUS
CN 19H-9,11-Ethenopyrimido[4,5-b]pyrrololo[1,2-1]1,6,1,9,12]benzoxatriazacyclopentadecine-14,19(5H,13H)-dione, 3-chloro-16,17,18,18a,20,21-hexahydro-22-methoxy- (CA INDEX NAME)




RN 807641-43-6 ZCPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-11-(1-hydroxyethyl)-20-methoxy- (CA INDEX NAME)




RN 807641-44-7 ZCPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-(1-methylethyl)- (CA INDEX NAME)



RN 807641-45-8 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-11-(hydroxymethyl)-20-methoxy- (CA INDEX NAME)




RN 807641-46-9 ZCPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-13-(hydroxymethyl)-22-methoxy- (CA INDEX NAME)




RN 807641-47-0 ZCPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-methyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-48-1 ZCPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11,11-dimethyl- (CA INDEX NAME)




RN 807641-49-2 ZCPLUS
 CN 13H-9,11-Ethenopyrimido[4,5-b]pyrrole-11,2-14H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-14,19(8H,13H)-dione, 2-chloro-16,17,18,18a,20,22-hexahydro-17-hydroxy-22-methoxy- (CA INDEX NAME)




RN 807641-50-5 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,15]benzodiazazoclooctadecin-15(8H)-20-chloro-9,12,13,14,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-51-6 ZCPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine, 20-chloro-9,10,11,12,13,14,15,16,17,22-decahydro-23-methoxy-16-methyl- (CA INDEX NAME)




RN 807641-52-7 ZCPLUS
 CN 16H-4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-10-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 807641-53-8 ZCPLUS
 CN 23H-9,12-Etheno-13H-pyrimido[4,5-b]pyrrole-1,2-1[6,1,12,15]benzoxatriazacyclooctadecine-17,22(5H,14H)-dione, 3-chloro-15,16,19,20,21,21a,22,24-octahydro-25-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-54-9 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclobexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11,11-dimethyl- (9CI) (CA INDEX NAME)




RN 807641-55-0 ZCPLUS
 CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-13-methyl- (CA INDEX NAME)




RN 807641-56-1 ZCPLUS
 CN 16H-4,6-Etheno-13H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-(2-methylpropyl)- (CA INDEX NAME)




RN 807641-57-2 ZCPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14,14-dimethyl- (CA INDEX NAME)




RN 807641-58-3 ZCPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-(phenylinethyl)- (CA INDEX NAME)




RN 807641-59-4 ZCPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-methyl- (CA INDEX NAME)




RN 807641-60-7 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][1,2-16,9,12]benzoxatriazacyclohexadecine-9,14(8H,15H)-dione, 20-chloro-11,12,13,13a,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-61-8 ZCPLUS
CN 14H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-(2-methylpropyl)- (CA INDEX NAME)




RN 807641-62-9 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 807641-63-0 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-(1-hydroxyethyl)-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-64-1 ZCPLUS
CN 14H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13,13-dimethyl- (CA INDEX NAME)




RN 807641-65-2 ZCPLUS
CN 14H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-(phenylinethyl)- (CA INDEX NAME)




RN 807641-66-3 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-14-(1-hydroxyethyl)-23-methoxy- (CA INDEX NAME)



RN 807641-67-4 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-11-(hydroxymethyl)-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-68-5 ZCPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclohexadecine-9,14(8H,15H)-dione, 20-chloro-11,12,13,13a,16,17-hexahydro-12-hydroxy-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-69-6 ZCPLUS
CN Carbamic acid, ((1*S*)-20-chloro-8,9,10,11,12,13,14,15,16,17-decahydro-23-methoxy-15-oxo-4,6-etheno-1*H*-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclooctadecine-14-yl)-, 1,1-dimethyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-70-9 ZCPLUS
CN 14*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,9,12,1]benzotrioxazacyclohexadecine, 18-chloro-8,9,11,12,15,20-hexahydro-21-methoxy- (CA INDEX NAME)




RN 807641-71-0 ZCPLUS
CN 8*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-11(8*H*)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy-13-methyl- (CA INDEX NAME)


RN 807641-75-4 ZCPLUS
CN 12*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8*H*,13*H*)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy- (CA INDEX NAME)




RN 807641-76-5 ZCPLUS
CN 4,6-Etheno-8*H*-pyrimido[4,5-b]pyrrolo[2,1-1][6,1,10,13]benzoxatriazacyclohexadecine-12,15(9*H*,12*A**H*)-dione, 20-chloro-1,10,11,13,14,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-77-6 ZCPLUS
CN 4,6-Etheno-12*H*-pyrimido[4,5-b]pyrrolo[2,1-1][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 20-chloro-1,8,9,10,11,12*A*,13,14,15,17-deahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-78-7 ZCPLUS
CN 4,6-Etheno-1*H*-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclohexadecine-9,13(8*H*,10*H*)-dione, 18-chloro-11,12,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)





RN 807641-72-1 ZCPLUS
CN 8*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclooctadecine-11(8*H*)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807641-73-2 ZCPLUS
CN 12*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA INDEX NAME)




RN 807641-74-3 ZCPLUS
CN 4,6-Etheno-1*H*-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclohexadecine-11(8*H*)-one, 18-chloro-9,10,12,13,14,15-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-79-8 ZCPLUS
CN 16*H*-4,6-Etheno-6*H*-pyrimido[4,5-b][6,1,11,16]benzoxatriazacyclononadecine-11,16(8*H*,17*H*)-dione, 23-chloro-9,10,12,13,14,15,18,23-octahydro-24-methoxy- (CA INDEX NAME)




RN 807641-80-1 ZCPLUS
CN 4,6-Etheno-1*H*-pyrimido[4,5-b][6,1,11,15]benzoxatriazacyclooctadecine-11,15(8*H*,12*H*)-dione, 20-chloro-9,10,13,14,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-81-2 ZCPLUS
CN 4,6-Etheno-1*H*-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8*H*,15*H*)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 807641-82-3 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 807641-83-4 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 807641-84-5 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-85-6 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 19-chloro-16-fluoro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-86-7 ZCPLUS
 CN 8H-4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-16-fluoro-9,10,12,13,14,19-hexahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN 807641-87-8 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 17-chloro-16-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA INDEX NAME)




RN 807641-88-9 ZCPLUS
 CN 8H-4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-16-fluoro-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807641-89-0 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807641-90-3 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807641-91-4 ZCPLUS
 CN 8H-4,6-Etheno-1H-pyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-9,10,11,12,14,15,16,21-octahydro-22-methoxy- (CA INDEX NAME)




RN 807641-92-5 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(8H)-one, 19-chloro-10-ethyl-8,9,10,11,13,14,15,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-93-6 ZCPLUS
 CN 1,22-Etheno-2H,17H-pyrimido[4,5-b]pyrrolo[2,1-n][6,1,9,12]benzoxatriazacycloheptadecin-14(15H)-one, 7-chloro-10,11,12,13,18,19,19a,20-octahydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807641-94-7 ZCPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclooctadecin-13(8H)-one, 20-chloro-9,10,11,12,14,15,16,17-octahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-95-8 ZCPLUS
CN 4,6-Etheno-4,6-dimethano-3H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-15(1H)-one, 22-chloro-9,10,11,12,16,17,18,19-octahydro-26-methoxy- (9CI) (CA INDEX NAME)




RN 807641-97-0 ZCPLUS
CN 18,9,12-Ethano-4,6-ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-14(13H)-one, 21-chloro-8,9,10,11,15,16,17,18,19-octahydro-26-methoxy- (9CI) (CA INDEX NAME)




RN 807641-98-1 ZCPLUS
CN 9H-10,12-Ethano-4,6-etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-15(1H)-one, 22-chloro-9,10,11,12,16,17,18,19-octahydro-27-methoxy- (9CI) (CA INDEX NAME)




RN 807641-99-2 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-10-[(2-hydroxymethyl)-hydroxymethyl]ethyl|amino]acetyl-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-00-8 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-10-[(2-(hydroxymethyl)-4-morpholinyl)acetyl]-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-01-9 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(2-(4-pyridinyl)ethyl)amino]acetyl- (9CI) (CA INDEX NAME)




RN 807642-02-0 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-10-[(2-(dimethylamino)ethyl)methylamino]acetyl- (9CI) (CA INDEX NAME)




RN 807642-03-1 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(2-methoxymethyl)amino]acetyl- (9CI) (CA INDEX NAME)




RN 807642-04-2 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(3-methoxypropyl)amino]acetyl- (9CI) (CA INDEX NAME)




RN 807642-05-3 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(4-morpholinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 807642-06-4 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 807642-07-5 ZCPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolid[2,1-n][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 21-chloro-20-fluoro-1,9,10,11,12,13a,14,15,16,18-decanhydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807642-08-6 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacycloheptadecine-11(8H)-thione, 19-chloro-18-fluoro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-09-7 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine, 19-chloro-1,8,9,10,11,12,13,14,15,16-decahydro-22-methoxy-15-methyl- (9CI) (CA INDEX NAME)




RN 807642-10-0 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine, 17-chloro-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (9CI) (CA INDEX NAME)




RN 807642-11-1 ZCPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-13-(1-hydroxyethyl)-22-methoxy- (CA INDEX NAME)




RN 807642-12-2 ZCPLUS
 CN 12H-4,6-Etheno-13,17-methanopyrimido[4,5-b][6,1,10,16]benzoxatriazacyclononadecin-12-one, 21-chloro-1,8,9,10,11,13,14,15,16,18-decahydro-25-methoxy- (CA INDEX NAME)




RN 807642-13-3 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl- (CA INDEX NAME)




RN 807642-14-4 ZCPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-15-ethyl-9,10,11,12,14,15,16,21-octahydro-22-methoxy- (CA INDEX NAME)




RN 807642-15-5 ZCPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-9,10,11,12,14,15,16,21-octahydro-22-methoxy-14,15-dimethyl- (CA INDEX NAME)




RN 807642-17-7 ZCPLUS
 CN Benzonitrile, 3-(8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecin-17-yl)- (CA INDEX NAME)




RN 807642-18-8 ZCPLUS
 CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadec-11(8H)-one, 19-chloro-1,9,10,11a,12,13,14,16-octahydro-13-hydroxy-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-19-9 ZCPLUS
 CN 13,16-Ethano-4,6-etheno-8H-pyrimido[4,5-b][6,1,9,12,15]benzoxatetraazacycloheptadecin-11(12H)-one, 20-chloro-1,9,10,14,15,17-hexahydro-25-methoxy- (9CI) (CA INDEX NAME)




RN 807642-20-2 ZCPLUS
 CN 8H-12,15-Ethano-4,6-ethenopyrimido[4,5-b][6,1,9,14]benzoxatriazacycloheptadecin-11(12H)-one, 19-chloro-1,9,10,13,14,16-hexahydro-24-methoxy- (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 807642-21-3 ZCPLUS
 CN 4,6-Etheno-12,16-methano-16H-pyrimido[4,5-b][6,1,9,15]benzoxatriazacyclooctadecin-11(8H)-one, 20-chloro-1,9,10,12,13,14,15,17-octahydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807642-22-4 ZCPLUS
 CN 8H-4,6-Etheno[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy-12,13-dimethyl- (CA INDEX NAME)




RN 807642-23-5 ZCPLUS
 CN 8H-4,6-Etheno[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-13-ethyl-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807642-24-6 ZCPLUS
 CN 8H-4,6-Etheno[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-12-(hydroxymethyl)-20-methoxy- (CA INDEX NAME)



RN 807642-28-0 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-14-ethyl-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807642-29-1 ZCPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-13-(hydroxymethyl)-21-methoxy- (CA INDEX NAME)




IT 807639-88-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)
 RN 807639-88-9 ZCPLUS
 CN Boronic acid, (8,9,10,11,12,13-hexahydro-20-methoxy-4,6-etheno-1H-pyrimido[4,5-b][6,13,1]benzodioxazaazacyclopentadecin-17-yl)- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807642-25-7 ZCPLUS
 CN 4,6-Etheno-12H-pyrimido[4,5-b]pyrrolo[2,1-1]6,1,10,13-benzoxatriazacyclohexadecin-12-one, 20-chloro-1,8,9,10,11,12a,13,14,15,17-decahydro-14-hydroxy-23-methoxy- (9CI) (CA INDEX NAME)




RN 807642-26-8 ZCPLUS
 CN 14,17-Ethano-4,6-ethenopyrimido[4,5-b][6,1,10,13,16]benzoxatetraazacyclononadecin-12(13H)-one, 21-chloro-1,8,9,10,11,15,16,18-octahydro-26-methoxy- (9CI) (CA INDEX NAME)



RN 807642-27-9 ZCPLUS
 CN 13,16-Ethano-4,6-etheno-16H-pyrimido[4,5-b][6,1,10,15]benzoxatriazacyclooctadecin-12(13H)-one, 20-chloro-1,8,9,10,11,14,15,17-octahydro-25-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN
 AN 1994:655685 ZCPLUS
 DN 121:255685
 OREF 121:4667
 TI 3-Amino-4-imino-4H-thieno[3,4-c][1]benzopyran
 with some selected dienophiles
 AU Nyondi-Bongue, E.; Sophie Fondjo, E.; Tanee Fomum, Z.; Doepp, Dietrich
 CS Fac. Sci., Univ. Yaounde, Yaounde, Cameroon
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1994), (15), 2191-5
 CODEN JCPRA4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 121:255685
 GI

L14 ANSWER 3 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN (Continued)




OSC.G 12 THERE ARE 12 CAPIUS RECORDS THAT CITE THIS RECORD (12 CITINGS)



AB 3-Amino-4-imino-4H-thieno[3,4-c][1]benzopyran (I) adds di-Me maleate and di-Me acetylenedicarboxylate in a (4 + 2) mode across the thiophene ring and reacts with 2,3-dichloro-1,4-naphthoquinone by substitution of both chlorine atoms. All primary adducts, however, are unstable under the reaction conditions. The structures of the final products, e.g. II, have been assigned from their spectral data and their formation has been rationalized in terms of transformations available to the assumed primary products.

IT 158529-61-4P 158529-62-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RN 158529-61-4 ZCPLUS
 [1]Benzopyran[2,3,4-de]quinazoline-2,3-dicarboxylic acid, 5-methyl-,
 2,3-dimethyl ester (CA INDEX NAME)




RN 158529-62-5 ZCPLUS
 CN [1]Benzopyran[2,3,4-de]quinazoline-2,3-dicarboxylic acid,
 5-(trifluoromethyl)-, 2,3-dimethyl ester (CA INDEX NAME)

L14 ANSWER 4 OF 4 ZCPLUS COPYRIGHT 2009 ACS on STN
 AN 1971:22728 ZCPLUS
 DN 74:22728
 OREF 74:3675a, 3678a
 TI Reactions of 4-dicyanomethylene-2-phenyl-4H-1-benzopyran and some
 benzocyclic nucleophiles
 AU Reynolds, George Arthur; Van Allan, James A.; Petropoulos, C. C.
 CS Res. Lab., Eastman Kodak Co., Rochester, NY, USA
 SO Journal of Heterocyclic Chemistry (1970), 7(5), 1061-9
 CODEN: JHETAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 74:22728
 GI For diagram(s), see printed CA Issue.

AB 4-Dicyanomethylene-2-phenyl-4H-1-benzopyran (I) reacts with primary amines under mild conditions to give 3-alkyl-5-alkylimino-2-phenyl-3,4-dihydro-5H-[1]benzopyran[3,4-c]pyridin-5-ones (II) which, in turn, are hydrolyzed by acid to 4-imino-3-alkyl-2-phenyl-3,4-dihydro-5H-[1]benzopyran[3,4-c]pyridin-5-ones. When more vigorous conditions are employed for the reaction of I with primary amines, Dimroth rearrangement takes place and the products are 4-alkyl(or aryl)amino-5-alkyl(or aryl)imino-2-phenyl-5H-[1]benzopyran[3,4-c]pyridine. The latter compds. are hydrolyzed by acid to the corresponding 5-pyridone derivs. The reactions of I with piperidine gives 2-phenyl-4-piperidyl-5H-[1]benzopyran[3,4-c]pyridin-5-one. NaOMe reacts with I to give 3-cyano-2-methoxy-(2-methoxyphenyl)-6-phenylpyridine. Two benzologs of I were allowed to react with primary and secondary amines and the products are analogous to those obtained from I.

IT 30155-82-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of)
 RN 30155-82-9 ZCPLUS
 CN Naphtho[2',1':5,6]pyrano[2,3,4-de]quinazoline-3-carbonitrile,
 2,5-diphenyl- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPIUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

=> d his
(FILE 'HOME' ENTERED AT 12:25:19 ON 18 NOV 2009)
FILE 'ZCPLUS' ENTERED AT 12:25:29 ON 18 NOV 2009
L1 1 US20070078132 /PN
FILE 'REGISTRY' ENTERED AT 12:25:40 ON 18 NOV 2009
FILE 'ZCPLUS' ENTERED AT 12:25:41 ON 18 NOV 2009
L2 TRA L1 1- RN : 61 TERMS
FILE 'REGISTRY' ENTERED AT 12:25:41 ON 18 NOV 2009
L3 61 SEA L2
L4 STR
L5 16 L4
L6 54 L3 AND RSD/FA
L7 415 L4 FULL
SAV TEM J512C1/A L7
L8 23 L7 AND L3
L9 392 L7 NOT L8
FILE 'ZCPLUS' ENTERED AT 12:40:42 ON 18 NOV 2009
L10 1 L8
L11 11 L9
L12 2 L11 AND (PRD<=20041215 OR AD<=20041215)
L13 2 L11 AND PD<=20031218
L14 4 L12-13
L15 7 L11 NOT L14

=>